Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sebastian Frechen

Showing results (1-10 of 42) with videos related to

Pageof 5
Sort By:
Drug Safety|June 8, 2013
Author's Reply to Kotlinska-Lemieszek: "Should Midazolam Drug-Drug Interactions Be of Concern to Palliative Care Physicians?"Sebastian Frechen, Jan Gaertner
Pharmaceutical Research|April 21, 2022
Quality Assurance of PBPK Modeling Platforms and Guidance on Building, Evaluating, Verifying and Applying PBPK Models Prudently under the Umbrella of Qualification: Why, When, What, How and By Whom?Sebastian Frechen, Amin Rostami-Hodjegan
CPT: Pharmacometrics & Systems Pharmacology|November 16, 2021
Physiologically-based pharmacokinetic modeling to predict CYP3A4-mediated drug-drug interactions of finerenoneThomas Wendl, Sebastian Frechen, Michael Gerisch, et al.
Palliative Medicine|July 9, 2011
Drug interactions in palliative care--it's more than cytochrome P450Jan Gaertner, Klaus Ruberg, Grit Schlesiger, et al.
Therapeutic Advances in Urology|July 28, 2017
Assessment of inhibitory effects on major human cytochrome P450 enzymes by spasmolytics used in the treatment of overactive bladder syndromeDominik Dahlinger, Sevinc Aslan, Markus Pietsch, et al.
The Oncologist|February 24, 2012
Palliative care consultation service and palliative care unit: why do we need both?Jan Gaertner, Sebastian Frechen, Markus Sladek, et al.
CPT: Pharmacometrics & Systems Pharmacology|October 3, 2024
PBPK modeling: What is the role of CYP3A4 expression in the gastrointestinal tract to accurately predict first-pass metabolism?Justine Henriot, André Dallmann, François Dupuis, et al.
Drug Safety|July 20, 2012
Drug interactions in dying patients: a retrospective analysis of hospice inpatients in GermanySebastian Frechen, Anna Zoeller, Klaus Ruberg, et al.
Journal of Clinical Pharmacology|May 6, 2024
In-Depth Analysis of the Selection of PBPK Modeling Tools: Bibliometric and Social Network Analysis of the Open Systems Pharmacology CommunityAndré Dallmann, Donato Teutonico, Stephan Schaller, et al.
Journal of Pharmacological and Toxicological Methods|November 4, 2015
Development and validation of an in vitro, seven-in-one human cytochrome P450 assay for evaluation of both direct and time-dependent inhibitionDominik Dahlinger, Sabrina Duechting, Daniela Nuecken, et al.
Pageof 5

Showing results (1-10 of 42) with videos related to

Sort By:
Pageof 5
Drug Safety|June 8, 2013
Author's Reply to Kotlinska-Lemieszek: "Should Midazolam Drug-Drug Interactions Be of Concern to Palliative Care Physicians?"Sebastian Frechen, Jan Gaertner
Pharmaceutical Research|April 21, 2022
Quality Assurance of PBPK Modeling Platforms and Guidance on Building, Evaluating, Verifying and Applying PBPK Models Prudently under the Umbrella of Qualification: Why, When, What, How and By Whom?Sebastian Frechen, Amin Rostami-Hodjegan
CPT: Pharmacometrics & Systems Pharmacology|November 16, 2021
Physiologically-based pharmacokinetic modeling to predict CYP3A4-mediated drug-drug interactions of finerenoneThomas Wendl, Sebastian Frechen, Michael Gerisch, et al.
Palliative Medicine|July 9, 2011
Drug interactions in palliative care--it's more than cytochrome P450Jan Gaertner, Klaus Ruberg, Grit Schlesiger, et al.
Therapeutic Advances in Urology|July 28, 2017
Assessment of inhibitory effects on major human cytochrome P450 enzymes by spasmolytics used in the treatment of overactive bladder syndromeDominik Dahlinger, Sevinc Aslan, Markus Pietsch, et al.
The Oncologist|February 24, 2012
Palliative care consultation service and palliative care unit: why do we need both?Jan Gaertner, Sebastian Frechen, Markus Sladek, et al.
CPT: Pharmacometrics & Systems Pharmacology|October 3, 2024
PBPK modeling: What is the role of CYP3A4 expression in the gastrointestinal tract to accurately predict first-pass metabolism?Justine Henriot, André Dallmann, François Dupuis, et al.
Drug Safety|July 20, 2012
Drug interactions in dying patients: a retrospective analysis of hospice inpatients in GermanySebastian Frechen, Anna Zoeller, Klaus Ruberg, et al.
Journal of Clinical Pharmacology|May 6, 2024
In-Depth Analysis of the Selection of PBPK Modeling Tools: Bibliometric and Social Network Analysis of the Open Systems Pharmacology CommunityAndré Dallmann, Donato Teutonico, Stephan Schaller, et al.
Journal of Pharmacological and Toxicological Methods|November 4, 2015
Development and validation of an in vitro, seven-in-one human cytochrome P450 assay for evaluation of both direct and time-dependent inhibitionDominik Dahlinger, Sabrina Duechting, Daniela Nuecken, et al.
Pageof 5